NCT01475370 - Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 24, 2012

Primary Completion Date

December 22, 2016

Study Completion Date

December 22, 2016

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

OCV-501

"1. Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001.~2. After the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the recommended dose."

Trial Locations (1)

Unknown

National Cancer Center, Tokyo